Quercetin and its derivatives: Synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 2, 2009, Pages 138-161

  Hirpara, Ketan V ^a   Aggarwal, Pawan ^a   Mukherjee, Amrita J ^a   Joshi, Narendra J ^a   Burman, Anand C ^a  

^a DABUR RESEARCH FOUNDATION   (India)

Author keywords

Anticancer; Flavanoid; Glycoside; QC12; Quercetin; Synthesis

Indexed keywords

3 METHOXYFLAVONE DERIVATIVE; 3',4',7 TRIMETHOXYMETHYLQUERCETIN; 4' HYDROXY 7 BENZYL 3,3',5 TRIBENZOYLOXYFLAVONE; 4' O METHYLQUERCETIN; 7 O BENZYLQUERCETIN TETRAACETIC ACID; ANTHOCYANIDIN DERIVATIVE; ANTINEOPLASTIC AGENT; ASCORBIC ACID; FLAVANOL DERIVATIVE; FLAVANONE DERIVATIVE; FLAVONE DERIVATIVE; FLAVONOID; FLAVONOL DERIVATIVE; ISOFLAVONE DERIVATIVE; PRODRUG; QUERCETIN; QUERCETIN 3 BETA GALACTOSIDASE; QUERCETIN 3 METHYL ETHER; QUERCETIN 3 O BETA GLUCORONIDE; QUERCETIN 3 O GLYCOSIDE DERIVATIVE; QUERCETIN 3',4',5,7 TETRABENZOIC ACID; QUERCETIN 7 O BETA GLUCOSIDE; QUERCETIN DERIVATIVE; QUERCETIN PENTA ACETIC ACID; RHAMNETIN; RHAMNETIN TETRAACETIC ACID; ROSIGLITAZONE; TAMARIXETIN; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; GLYCEMIC CONTROL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PHYSICAL CHEMISTRY; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; VASODILATATION; ANIMAL; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; NEOPLASM; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PRODRUGS; QUERCETIN;

EID: 64049109356     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009787313855     Document Type: Review

References (71)

1. U. S. News & World report Thursday, April 3, 2008.
2. http://www.who.int/cancer/en/
3. http://www.bentham.org/cmcaca/contabs/cmcaca2-6.htm
4. http://www.chiro.org/nutrition/ABSTRACTS/Quercetin_A_Review.shtml
5. Okamoto, T. Safety of quercetin for clinical application. Int. J. Mol. Med., 2005, 16, 275-278.
6. Formica, J. V.; Regelson, W. Review of the biology of Quercetin and related bioflavonoids. Food Chem. Toxicol., 1995, 33, 1061-1080.
7. Lamson, D. W. and Brignall, M. S. Antioxidants and Cancer III: Quercetin. Altern. Med. Rev., 2000, 5, 196-208.
8. Harwood, M.; Danielewska-Nikiel, B.; Borzelleca, J. F.; Flamm, G. W.; Williams, G. M. and Lines, T. C. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem. Toxicol., 2007, 45, 2179-2205.
9. Wu, X.; Cheng, Li.; Xiang, D. and Wei, Y. Synthesis of carbamate derivatives of quercetin by reaction with amino acid ester isocyanates. Lett. Org. Chem., 2005, 2, 535-538.
10. http://www.diet-and-health.net/Supplements/Quercetin.html
11. Hansen, R. K.; Oesterreich, S. and Lemieux, P. Quercetin inhibits heat shock protein induction but not heat shock factor DNA binding in human breast carcinoma cells. Biochem Biophys. Res. Commun., 1997, 239, 851-856.
12. 1. Cancer Res., 1996, 56, 210-217.
13. Koishi, M.; Hosokawa, N.; Sato, M.; Nakai A.; Hirayoshi K.; Hiraoka M.; Abe M.; Nagata K. Quercetin, an inhibitor of heat shock protein synthesis, inhibits the acquisition of thermotolerance in a human colon carcinoma cell line. Jpn. J. Cancer Res., 1992, 83, 1216-1222.
14. Talalay, P., Fahey, J. W., Holtzclaw, W. D., Prestera, T. and Zhang, Y. Toxicol. Lett. Chemo protection against cancer by phase 2 enzyme induction., 1995, 82-83, 173-179.
15. Zhang, Y., Talalay, P., Cho, C. G. and Posner, G. H. A major inducer of anti-carcinogenic protective enzymes from broccoli: Isolation and elucidation of structure. Proc. Natl. Acad. Sci. U.S.A., 1992, 89, 2399-2403.
16. Duthie, S. J., Johnson, W. and Dobson, V. L. The effect of dietary flavonoids on DNA damage (strand breaks and oxidized pyrimidines) and growth in human cells. Mut. Res., 1997, 390, 141-151.
17. Balabhadrapathruni, S., Thomas, T. J., Yurkow, E. J., Amenta, P. S. and Thomas, T. Effects of genistein and structurally related phytoestrogens on cell cycle kinetics and apoptosis in MDA-MB-468 human breast cancer cells. Oncol. Rep., 2000, 7, 3-12.
18. Kuo, S. M. Antiproliferative potency of structurally distinct dietary flavonoids on human colon cancer cells. Cancer Lett., 1996, 110, 41-48.
19. Scambia, G.; Ranelletti, F. O. and Benedetti, P. P. Quercetin induces type-II estrogen binding sites in estrogen-receptor-negative (MDA-MB231) and estrogen-receptor-positive (MCF-7) human breast cancer cell lines. Int. J. Cancer, 1993, 54, 462-466.
20. Avila, M. A.; Velasco, J. A.; Cansado, J. and Notario, V. Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468. Cancer Res., 1994, 54, 2424-2428.
21. Avila, M. A.; Velasco, J. A. and Harter, K. W. Quercetin as a modulator of the cellular neoplastic phenotype. Adv. Expl. Med. Biol., 1996, 401, 101-110.
22. Nigro, J. M.; Baker, S. J.; Preisinger, A. C.; Jessup, J. M.; Hostetter, R.; Cleary, K.; Bigner, S. H.; Davidson, N.; Baylin, S. and Devilee, P. Mutations in the p53 gene occur in diverse human tumour types. Nature, 1989, 342, 705-708.
23. Ferry, D. R.; Smith, A.; Malkhandi, J.; Fyfe, D. W.; deTakats, P. G.; Anderson, D.; Baker, J. and Kerr, D. J. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res., 1996, 2, 659-668.
24. Lamson, D. W. MS, ND and Brignall, M. S. ND. Antioxidants and Cancer III: Quercetin. Altern. Med. Rev., 2000, 5, 197-208.
25. Gulati, N.; Laudet, B.; Zohrabian, V. M.; Murali, R. and Jhanwar-Uniyal, M. The antiproliferative effect of Quercetin in cancer cells is mediated via inhibition of the PI3K-Akt/PKB pathway. Anticancer Res., 2006, 26, 1177-1181.
26. Soria, E. A.; Eynard, A. R.; Quiroga, P. L. and Bongiovanni, G. A. Differential effects of Quercetin and silymarin on arsenite-induced cytotoxicity in two human breast adenocarcinoma cell lines. Life Sci., 2007, 81, 1397-1402.
27. Lee, D.-H.; Szczepanski, M. and Lee, Y. Regulatory mechanisms of IL-2 and IFNγ suppression by q in T helper cells. J. Biochem. Pharmacol., 2008, 75, 2345-2355.
28. Boots, A. W.; Wilms, L. C.; Swennen, E. L.; Kleinjans, J. C.; Bast, A. and Haenen, G. R. In vitro and ex vivo anti-inflammatory activity of Quercetin in healthy volunteers. Nutrition, 2008, 24, 703-710.
29. Kuntz, S.; Wenzel, U. and Daniel, H. Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur. J. Nutr., 1999, 38, 133-142.
30. Rodriguez, J.; Yanez, J.; Vicente, V.; Alcaraz, M.; Benavente-Garcia, O.; Castillo, J.; Lorente, J. and Lozano, J. A. Effects of several flavonoids on the growth of B16F10 and SK-MEL-1 melanoma cell lines: relationship between structure and activity. Melanoma Res., 2002, 12, 99-107.
31. Nagao, T.; Abe, F.; Kinjo, J. and Okabe, H. Antiproliferative Constituents in Plants. 10. Flavones from the Leaves of Lantana montevidensis BRIQ. and Consideration of Structure-Activity Relationship. Biol. Pharm. Bull., 2002, 25, 875-879.
32. Daskiewicz, J. -B.; Depeint, F.; Viornery, L.; Bayet, C.; Comte-Sarrazin, G.; Comte, G.; Gee, J. M.; Johnson, I. T.; Ndjoko, K.; Hostettmann, K. and Barron, D. Effects of Flavonoids on Cell Proliferation and Caspase Activation in a Human Colonic Cell Line HT29: An SAR Study. J. Med. Chem., 2005, 48, 2790-2804.
33. Gross, A.; Borcherding, D. R.; Friedrich, D. and Sabol, J. S. A stereocontrolled approach to substituted piperidones and piperidines: flavopiridol D-ring analogs. Tetrahedron Lett., 2001, 42, 1631-1633.
34. Murthi, K. K.; Dubay, M.; McClure, C.; Brizuela, L.; Boisclair, M. D.; Worland, P. J.; Mansuri, M. M. and Pal. K. Structure-activity relationship studies of flavopiridol analogues. Bioorg. Med. Chem. Lett., 2000, 10, 1037-1041.
35. Jurd, L. [Alkylation of flavonol acetates. Chemistry and Industry, 1957, 1452-1453.
36. Jurd, L. Plant Polyphenols. V. Selective Alkylation of the 7-hydroxyl group in polyhydroxyflavones. J. Chem. Soc., 1958, 80, 5531-5536.
37. Kubota, O. and Perkin, A. G. A wandering of the acetyl group during methylation. J. Chem. Soc., 1925, 127, 1889.
38. Mahesh, V. B. C.; Neelakanton, S. and Seshadri, T. R. J. Sci. Ind. Res. (India), 1956, 15B, 287.
39. Jurd, L. and Rolle, L. A. Plant Polyphenols. IV. Migration of acetyl groups during alkylation of the partial acetates of Flavonoid compound. J. Chem. Soc., 1958, 80, 5527-5531.
40. Jurd, L. The selective alkylation of polyphenols. II. Methylation of 7-, 4′-, and 3′-Hydroxyl groups in flavonols. J. Org. Chem., 1962, 27, 1294-1297.
41. Bouktaib, M.; Lebrun, S.; Atmani, A. and Rolando, C. Hemisynthesis of all the O-monomethylated analogues of quercetin including the major metabolites, through selective protection of phenolic functions. Tetrahedron, 2002, 58, 10001-10009.
42. Yoo, H.; Kim, S. H.; Lee, J.; Kim, H. J.; Seo, S. H.; Chung, B. Y.; Jin, C. and Lee, Y. S. Synthesis and Antioxidant Activity of 3-Methoxyflavones. Bull. Korean Chem. Soc., 2005, 26, 2057-2060.
43. Gatto, M. T.; Falcocchio, S.; Grippa, E.; Mazzanti, G.; Battinelli, L.; Nicolosi, G.; Lambusta D. and Saso, L. Antimicrobial and Anti-Lipase Activity of Quercetin and its C2-C16 3-O-Acyl-Esters. Bioorg. Med. Chem., 2002, 10, 269-272.
44. Shetty, A. K.; Rashmi, R.; Rajan, M. G. R.; Sambaiah, K. and Salimath, P. V. Antidiabetic influence of quercetin in streptozotocin-induced diabetic rats. Nutr. Res. (New York, NY, United States), 2004, 24, 373-381.
45. Nuraliev, lu. N. and Avezov, G. A. The efficacy of quercetin in alloxan diabetes. Eks. Klin. Farmakol., 1992, 55, 42-44.
46. Momose, Y.; Meguro, K.; Ikeda, H.; Hatanka, C.; Oi, S. and Sohda, T. Studies on Antidiabetic Agents X. Synthesis and biological activities of pioglitazone and realted compounds. Chem. Pharm. Bull., 1991, 39, 1440-1445.
47. Cantello, B. C.; Cawthome, M. A.; Haigh, D.; Hindley, R. M.; Smith, S.A. and Thurlby, P. [[.omega.-(Heterocyclylamino)alkoxy]-benzyl]-2,4- thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem., 1994, 37, 3977-3985.
48. Lee, J. Y.; Park, W.-H.; Cho, M.-K.; Yun, H. J.; Chung, B.-H.; Pak, Y. K.; Hahn, H.-G. and Cheon, S. H. Design and synthesis of novel antidiabetic agents Arch. Pharm. Res., 2005, 28, 142-150.
49. De la Torre, M. D. L.; Tome, A. C.; Silva, A. M. S. and Cavaleiro, J. A. S. Synthesis of [60] fullerene-quercetin dyads. Tetrahedron Lett., 2002, 43, 4617-4620.
50. De la Torre, M. D. L.; Rodrigues, A. G. P.; Tome, A. C.; Silva, A. M. S. and Cavaleiro, J. A. S. [60] Fullerene-flavonoid dyads. Tetrahedron, 2004, 60, 3581-3592.
51. Birdsall, T. C. and Czap, A. F. Quercetin chalcone and methods related thereto. Thorne Res. Inc., US 5977184, 1999.
52. Yang, J.; Guo, J. and Yuan, J. In vitro antioxidant properties of rutin. LWT-Food Sci. Technol., 2008, 41, 1060-1066.
53. Farkas, L.; Vermes, B. and Nogradi, M. Transacylation reactions in the flavovoid series, VIII. Acta Chimica Academiae Scientiarum Hungaricae, 1972, 73, 107-111.
54. Zhou, J.; Hu, Y. Z. J. Zhejiang Univ. (Med. Sci.), 2002, 31, 410.
55. Chen, Z.; Hu, Y.; Wu, H. and Jiang, H. Synthesis and biological evaluation of flavonoids as vasorelaxant agents. Bioorg. Med. Chem. Lett., 2004, 14, 3949-3952.
56. pro: Structure-activity relationship studies reveal salient pharmacophore features. Bioorg. Med. Chem., 2006, 14, 8295-8306
57. Bouktaib, M.; Atmani, A. and Rolando, C. Regio- and stereoselective synthesis of the major metabolite of quercetin, quercetin-3-O-β-d-glucuronide. Tetrahedron Lett., 2002, 43, 6263-6266.
58. Iwagawa, T.; Kawasaki, J.-I.; Hase, T.; Sako, S.; Okubo, T.; Ishida, M. and Kim, M. An acetylated flavonol glycoside from Lasiobema japonica. Phytochemistry, 1990, 29, 1013-1014.
59. Okamura, H.; Mimura, A.; Yakou, Y.; Niwano, M. and Takahara, Y. Antioxidant activity of tannins and flavonoids in Eucalyptus rostrata. Phytochemistry, 1993, 33, 557-561.
60. Kim, H. J.; Woo, E. -R.; Shin, C. -G. and Park, H. A new flavonol glycoside gallate ester from Acer okamotanum and its inhibitory activity against human immunodeficiency virus-1 (HIV-1) integrase. J. Nat. Prod., 1998, 61, 145-148.
61. Li, M.; Han, X. and Yu, Biao. Synthesis of quercetin 3-O-(2″-galloyl)-α-1-arabinopyranoside. Tetrahedron Lett., 2002, 43, 9467-9470.
62. 1-3. J. Nutr., 2008, 138, 885-888.
63. Calis, P.; Galanopoulos, T.; Maxwell, M.; Khayat, A.; Graves, D.; Antoniades, H. N. and Alarco, M. Synthesis of inositol 2-phosphate-quercetin conjugates. Carbohydrate Res., 1996, 292, 83-90.
64. Dick, A. J. and Smith, K. C. Quercetin glucosides and galactosides: Substrates and inhibitors of apple β-galactosidase. J. Agric. Food Chem., 1990, 38, 923-926.
65. Du, Y.; Wei, G. and Linhardt, R. J. Total synthesis of quercetin 3-sopyhorotriside. J. Org. Chem., 2004, 69, 2206-2209.
66. Du, Y.; Wei, G. and Linhardt, R. J. The first total synthesis of calabricoside A. Tetrahedron Lett., 2003, 44, 6887-6890
67. Zhu, C.; Peng, W.; Li, Y.; Han X. and Yu, B. Synthesis of 3-O-(β-d-xylopyranosyl-(1→2)- β-d-glucopyranosyl)-3′-O-(β-d-glucopyranosyl) tamarixetin, the putative structure of aescuflavoside A from the seeds of Aesculus chinensis. Carbohydrate Res., 2006, 341, 1047-1051.
68. Golding, B. T.; Griffin, R. J.; Quarterman, C. P.; Slack, J. A. and Williams, J. G. Cobra Therapeutics Ltd. US 6,258,840, 2001.
69. Mulholland, P. J.; Ferry, D. R.; Anderson, D.; Hussain, S. A.; Young, A. M.; Cook, J. E.; Hodgkin, E.; Seymour, L. W. and Kerr, D. R. Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Ann. Oncol., 2001, 12, 245-248.
70. Picq, M.; Prigent, A. F.; Nemoz, G.; Andre, A. C. and Pacheco, H. Pentasubstituted quercetin analogs as selective inhibitors of particulate 3′,5′-cyclic-AMP phosphodiesterase from rat brain. J. Med. Chem., 1982, 25, 1192-1198.
71. Biasutto, L.; Marotta, E.; Marchi, U. D.; Zoratti, M. and Paradisi, C. Ester-Based Precursors to Increase the Bioavailability of Quercetin. J. Med. Chem., 2007, 50, 241-253.